Related Experiment Video
Updated: Jul 16, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
Genetic variants associated with triglyceride metabolism and fasting triglyceride concentrations: a systematic review
Dena A Nuwaylati1, Ronald P Mensink2, Peter J Joris2
1Department of Nutrition and Movement Sciences, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands (Nuwaylati, Mensink, and Plat); Division of Clinical Biochemistry, Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia (Nuwaylati).
Background And Objective:
The genetic background of hypertriglyceridemia is complex. In this systematic review and meta-analysis, we determined genetic variants associated with fasting triglyceride (TG) and very-low-density lipoprotein-TG (VLDL-TG) concentrations in European adults.
Methods:
We searched PubMed and the National Human Genome Research Institute-European Bioinformatics Institute (NHGRI-EBI) genome-wide association studies catalog for studies on genetic variants associated with fasting TG and VLDL-TG concentrations. We performed the meta-analysis on 23 variants from studies that met our criteria. A fixed-effects model was applied, with a random-effects model used when significant heterogeneity was detected. The Ensembl Variant Effect Predictor was used to annotate these variants.
Results:
Overall, 157 studies were included, of which 130 were used for meta-analysis. Overall, 1837 variants were related to fasting TG and/or VLDL-TG (P ≤ 0.05). Our meta-analysis revealed 11 genetic variants associated with fasting TG: rs58542926 in the transmembrane 6 superfamily member 2 (TM6SF2) gene, rs738409 in the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene, rs7903146 in the transcription factor 7-like 2 (TCF7L2) gene, rs320 and rs328 in the lipoprotein lipase (LPL) gene, and rs1801282 in the peroxisome proliferator-activated receptor γ2 (PPARγ2) gene were associated with lower TG concentrations, while rs693 in the apolipoprotein-B (APOB) gene, rs5128 in the apolipoprotein-c3 (APOC3) gene, rs662799 in the apolipoprotein A-V (APOA5) gene, rs662 in the paraoxonase 1 (PON1) gene, and rs1800588 in the hepatic lipase C (LIPC) gene were associated with higher TG concentrations. Five of those (rs58542926, rs738409, rs320, rs328, and rs1801282) were predicted to be deleterious to the protein function.
Conclusion:
This study identified variants associated with fasting TG and/or VLDL-TG concentrations in European adults, which may help in identifying genetically susceptible individuals and strengthening the accuracy of genetic risk prediction for TG-related outcomes.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenomics: Identification of New Drug Targets
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetics and Pharmacogenomics: Overview
